The company, best known for co-inventing the ChAdOx1 COVID-19 vaccine with the University of Oxford (now licenced to AstraZeneca), will relocate its headquarters to the site in spring 2022.
Vaccitech’s new facility will take over half of the newly constructed Zeus building at the campus, which is located just out of Oxford.
Accommodating a growing team
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. It has a pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs.
Its proprietary platform comprises modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans.
Vaccitech’s chief operating officer, Chris Ellis, said, “Vaccitech has a broad pipeline of programs in clinical trials and manufacturing for a biotechnology company of its size.
“This reflects the ambition, passion and drive that is felt right across the company and its investors as we strive to bring new immunotherapeutics and vaccines to the world.
“The need for new space designed primarily for state-of-the-art wet laboratory and offices, to house our growing team was our first priority, and staying within the Oxfordshire infrastructure, drove our decision to relocate to the Zeus building at Harwell Campus.”